Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union

William C. Gerth; Giuseppe Remuzzi; Giancarlo Viberti; Thierry Hannedouche; Alberto Martínez‐Castelao; Shahnaz Shahinfar; George W. Carides; Barry M. Brenner

doi:10.1046/j.1523-1755.62.s82.14.x

Related publications

Article2002

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL Study for the European Union

W.C. Gerth, Giancarlo Viberti, Giuseppe Remuzzi, Alberto Martínez‐Castelao, T Hannedouche, George W. Carides

Article2002

Losartan reduces the burden of ESRD: public health implications from the RENAAL study for the European Union

W.C. Gerth, T Hannedouche, Alberto Martínez‐Castelao, Giuseppe Remuzzi, Giancarlo Viberti, G Nocea, George W. Carides

Article2023

Economic burden of cardiovascular diseases in the European Union: a population-based cost study

Ramón Luengo-Fernández, Marjan Walli-Attaei, Alastair Gray, Aleksandra Torbica, Aldo Maggioni, Radu Huculeci, Firoozeh Bairami, Victor Aboyans, Adam Timmis, Panos Vardas, José Leal

Letter2022

Nutri-Score in tug-of-war between public health and economic interests in the European Union

Chantal Julia, Mathilde Touvier, Emmanuelle Kesse‐Guyot, Pilar Galán, Serge Hercberg

Article2000

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw, Jean‐Pierre Grünfeld, William F. Keane, Kiyoshi Kurokawa, Janet B. McGill, William E. Mitch, Hans Henrik Parving, Giuseppe Remuzzi, Arthur Barcelos Ribeiro, Mark Schluchter, Duane Snavely, Zhongxin Zhang, Roger L. Simpson, Denise Ramjit, Shahnaz Shahinfar, Renaal Study Investigators